Sponsored Links
| CalciMedica Initiates Phase I Clinical Trial Of First CRAC Channel Inhibitor (CCI) For Psoriasis |
 |
 |
 |
| Medical News - Eczema and Psoriasis | |||
|
CalciMedica, a biotechnology company developing small molecules to treat inflammatory and autoimmune diseases, announced that it has dosed the first cohort in a Phase 1 clinical trial of CM2489. CM2489 is a first-in-class calcium-release activated calcium (CRAC) channel inhibitor being studied as a once-daily oral therapeutic for patients with moderate-to-severe plaque psoriasis... Read more: Eczema / Psoriasis News From Medical News Today
|